The tumor immune microenvironment plays an important role in the response to treatment in HER2-positive breast cancer.27,28 However, it remains unclear whether the tumor immune microenvironment could be a predictive biomarker in the context of ADC treatment. The gene discussed is ERBB2; the disease is neoplasm.